Payment overview · 2025
General Payments
$794.84
10 reported records · 6 companies
Healthcare provider profile · identity verified
Darith S. Khay, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAN JOSE, CA · NPI 1295761609
Verified facts
What the public records show
CMS Open Payments records show Darith S. Khay, M.D. received $794.84 in general payments during 2025 across 10 reported records.
GlaxoSmithKline, LLC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $149.69 | 18.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.64 | 18.1% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $136.39 | 17.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.99 | 15.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $123.69 | 15.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $116.44 | 14.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $794.84 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $136.39 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $126.87 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $123.69 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $109.79 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.85 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 165 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 858 | 250 |
| Losartan Potassium | Losartan Potassium | 693 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 647 | 191 |
| Omeprazole | Omeprazole | 381 | 108 |
| Ezetimibe | Ezetimibe | 335 | 105 |
| Tradjenta | Linagliptin | 257 | 48 |
| Alendronate Sodium | Alendronate Sodium | 237 | 78 |
| Metformin Hcl | Metformin Hcl | 231 | 68 |
| Montelukast Sodium | Montelukast Sodium | 225 | 69 |
| Meclizine Hcl | Meclizine Hcl | 218 | 72 |
| Famotidine | Famotidine | 210 | 52 |
| Glipizide Er | Glipizide | 208 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 47 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 189 | 72 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 178 | 65 |
| Raloxifene Hcl | Raloxifene Hcl | 173 | 48 |
| Metformin Hcl Er | Metformin Hcl | 169 | 50 |
| Jardiance | Empagliflozin | 165 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 156 | 45 |
| Gabapentin | Gabapentin | 151 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 45 |
| Icosapent Ethyl | Icosapent Ethyl | 141 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 35 |
| Carvedilol | Carvedilol | 135 | 38 |
| Eliquis | Apixaban | 132 | 25 |
| Celecoxib | Celecoxib | 126 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 39 |
| Baclofen | Baclofen | 122 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 29 |
| Simvastatin | Simvastatin | 116 | 33 |
| Allopurinol | Allopurinol | 114 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 37 |
| Finasteride | Finasteride | 107 | 31 |
| Pregabalin | Pregabalin | 107 | 29 |
| Hydrocortisone | Hydrocortisone | 103 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 98 | 29 |
| Ibuprofen | Ibuprofen | 94 | 28 |
| Furosemide | Furosemide | 92 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 88 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 22 |
| Vascepa | Icosapent Ethyl | 82 | 15 |
| Benazepril Hcl | Benazepril Hcl | 81 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 27 |
| Farxiga | Dapagliflozin Propanediol | 77 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 22 |
| Lorazepam | Lorazepam | 68 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 68 | 13 |
| Januvia | Sitagliptin Phosphate | 66 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 19 |
| Azelastine Hcl | Azelastine Hcl | 60 | 18 |
| Tramadol Hcl | Tramadol Hcl | 58 | 12 |
| Meloxicam | Meloxicam | 54 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 43 |
| Loperamide | Loperamide Hcl | 52 | 43 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 47 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 16 |
| Terazosin Hcl | Terazosin Hcl | 49 | 13 |
| Nystatin | Nystatin | 46 | 18 |
| Trazodone Hcl | Trazodone Hcl | 46 | 11 |
| Ketoconazole | Ketoconazole | 43 | 12 |
| Cephalexin | Cephalexin | 40 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 38 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Lactulose | Lactulose | 38 | suppressed |
| Benzonatate | Benzonatate | 36 | 14 |
| Fluocinonide | Fluocinonide | 34 | 12 |
| Nateglinide | Nateglinide | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 13 |
| Sulindac | Sulindac | 30 | 12 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 28 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 27 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | suppressed |
| Lisinopril | Lisinopril | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 21 | 15 |
| Prednisone | Prednisone | 21 | 15 |
| Linzess | Linaclotide | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 12 |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Entecavir | Entecavir | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Felodipine Er | Felodipine | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Prolia | Denosumab | 17 | 15 |
| Qvar Redihaler | Beclomethasone Dipropionate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $794.84 · 10 records | GlaxoSmithKline, LLC. | AREXVY, CAPVAXIVE, GARDASIL 9, JARDIANCE, KRYSTEXXA, M-M-R II, PENMENVY, PYRUKYND, REPATHA, VAXNEUVANCE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error